Testing the shingles vaccine response after bone marrow transplant
Treatments studied
Part of Infections clinical trials.
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are 12 to 36 months after your donor stem cell transplant
- Your transplant donor source was a matched relative, matched unrelated donor, or cord blood
- You have (or previously had) a blood cancer or blood-related illness, and you are not currently experiencing a relapse
- You are medically well enough for vaccination (not acutely ill) and can do intramuscular injections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the shingles vaccine in young adults who have had a solid organ transplant (like a kidney or liver) more than a year ago. The goal is to see if the vaccine works well and is safe for people on stable anti-rejection medicines.
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
This study tests whether an extra dose of the Shingrix shingles vaccine can boost protection in people who have had a solid-organ transplant. If you already received both doses of Shingrix after your transplant, this trial will give you an additional dose to see if it further strengthens your immune response.
This trial tests whether the shingles vaccine (RZV) is safe and works well for organ transplant recipients and their household members. It also includes people on dialysis or certain immunosuppressants.
This study tests a new shingles vaccine for people 40 and older. It looks at safety, how well the body responds, and whether it can prevent shingles.
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
Hear when a new Shingles trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.